Athernal Bio
Company Details
About: Athernal bio is developing the first immunotherapies for high-risk clonal haematopoiesis — addressing blood cancer precursor condition with the aim of stopping cancer before it starts through early and proactive therapeutic intervention.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Athernal Bio | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.